Pulsenmore Taps Med-Tech Veteran to Lead U.S. Expansion

  • Pulsenmore appointed David Woods as Chief Commercial Officer to lead U.S. expansion.
  • Woods brings 25 years of med-tech leadership experience from Creo Medical and PENTAX Medical.
  • Pulsenmore launched U.S. commercial operations following FDA De Novo authorization of its home prenatal ultrasound system.
  • The company is exploring opportunities tied to the federal Rural Health Transformation Program (RHTP).
  • Pulsenmore has entered a strategic collaboration with Ouma Health.

Pulsenmore's appointment of David Woods underscores its aggressive push into the U.S. maternal healthcare market, where demand for accessible prenatal care and federal rural health investments are creating new opportunities. The move comes as telemedicine and remote monitoring technologies gain traction, positioning Pulsenmore to address gaps in maternal care access, particularly in underserved and rural communities. The strategic collaboration with Ouma Health further bolsters its commercial strategy, aligning with broader industry trends toward decentralized healthcare delivery.

Market Penetration
How Pulsenmore will leverage David Woods' experience to accelerate U.S. market adoption of its home prenatal ultrasound system.
Regulatory Alignment
Whether Pulsenmore can sustain momentum from FDA authorization and capitalize on federal rural health investments.
Strategic Partnerships
The pace at which Pulsenmore's collaboration with Ouma Health translates into tangible commercial outcomes.